NASDAQ · AMLX
Amylyx Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AMLX: Nov 5, 2026
Amylyx Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.38. The reported EPS for the same quarter last year was $-0.37.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.38 | $-0.35 | $-0.40 | 4 |
| Dec 2026 | $-0.37 | $-0.34 | $-0.41 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · The Motley Fool · Barchart · Zacks- MarketBeat · Oct 3, 3:02 AM EDTAmylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH TreatmentAmylyx Stock: Why the Full Pipeline Story MattersAmylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to th
- The Motley Fool · Sep 1, 9:50 AM EDTIs GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet.
- The Motley Fool · Aug 30, 12:35 PM EDTShould Eli Lilly Investors Be Worried About a Threat From Amylyx?Eli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026.
- The Motley Fool · Aug 21, 6:00 PM EDTWhy Amylyx Pharmaceuticals Blasted Nearly 79% Higher This WeekAnalysts also raised their price targets on the company.
- Barchart · Aug 19, 2:43 PM EDTStocks Finish Lower as Chipmakers and AI Stocks FallThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.69% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -1.68%. E-mini S&P futures (ESU26 ) fell -0.69%, and September E-mini…
- Zacks · Aug 19, 12:18 PM EDTAMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study WinAmylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.
- RTTNews · Aug 19, 4:21 AM EDTBiotech Stocks At 52-Week Highs – AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL(RTTNews) – The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.
- RTTNews · Aug 19, 2:21 AM EDTAmylyx Unveils $350 Mln Offering Of Shares After Positive Avexitide Phase 3 Results(RTTNews) – Amylyx Pharmaceuticals, Inc. (AMLX), a clinical-stage pharmaceutical company, on Tuesday announced that it has commenced an underwritten public offering of $350 million in shares of its common stock.
- The Motley Fool · Aug 18, 7:30 PM EDTWhy Amylyx Pharmaceuticals Stock Skyrocketed TodayAmylyx is developing a GLP-1 treatment for people with chronic low blood sugar.
- Barchart · Aug 18, 6:44 PM EDTChipmaker Sell-Off Weighs on Stock IndicesThe S&P 500 Index ($SPX ) (SPY ) is down by -0.61% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.76%. E-mini S&P futures (ESU26 ) are down -0.68%, and September E-mini…
- Barchart · Aug 18, 5:44 PM EDTStocks Retreat as Global Bond Yields RiseThe S&P 500 Index ($SPX ) (SPY ) is down by -0.42% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.17%. E-mini S&P futures (ESU26 ) are down -0.51%, and September E-mini…
- BNK Invest · Aug 18, 5:33 PM EDTNotable Tuesday Option Activity: TGT, AMLX, TJXAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Target Corp (Symbol: TGT), where a total of 47,074 contracts have traded so far, representing approximately 4.7 million underlying shares. That amounts to about 130.4% o
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Amylyx Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.